Factors associated with placebo response rate in randomized controlled trials of antiseizure medications for focal epilepsy
These results can assist future RCTs in estimating the expected placebo responder rate, which may lead to more reliable power estimates. Higher placebo responder rate was associated with markers of less-refractory epilepsy. There were concerning significant differences in placebo responder rate by country and geographic region as well as an elevated placebo responder rate in participants with baseline seizure frequency close to the minimum eligibility criteria.
Authors
- Wesley T. Kerr (ORCID: https://orcid.org/0000-0002-5546-5951)
- Jacqueline A. French (ORCID: https://orcid.org/0000-0003-2242-8027)
- Maria Suprun (ORCID: https://orcid.org/0000-0001-9161-4021)
- Patrick Kwan (ORCID: https://orcid.org/0000-0001-7310-276X)
- Ernest Somerville (ORCID: https://orcid.org/0000-0001-8789-1122)
- Emilia Bagiella (ORCID: https://orcid.org/0000-0002-3582-6502)
- Katherine N. McFarlane (ORCID: https://orcid.org/0009-0000-0365-813X)
- Advith S. Reddy
- Neo Kok
Institutions
- The Royal Melbourne Hospital (AU)
- Mount Sinai Hospital (US)
- The University of Melbourne (AU)
- University of Pittsburgh (US)
- University of Michigan (US)
- The Alfred Hospital (AU)
- Mount Sinai Hospital (US)
- Prince of Wales Hospital (AU)
- Janssen (United States) (US)
- Monash University (AU)
- New York University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Epilepsia
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1111/epi.18197
- Citations
- 4
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.54
Funders
- American Epilepsy Society
- Pfizer
- GlaxoSmithKline
- American Brain Foundation
- American Academy of Neurology
- University of Pittsburgh
- Sunovion
- Upsher-Smith
- Eisai
- Epilepsy Society
- National Institutes of Health
- Medical Center, University of Pittsburgh
- National Institute of Neurological Disorders and Stroke